SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, being held July 23–27, 2021 in Las Vegas, Nevada.
In addition, Glaukos is sponsoring an educational symposium in conjunction with ASCRS and EyeWorld entitled “Innovation & Transformation in Glaucoma Management – The iStent inject® W: A Premium Solution” on Friday, July 23, 2021, at 5:00-6:00 pm PDT in Rooms L and GH at the Mandalay Bay South Convention Center. The faculty includes Richard Lindstrom, MD (Moderator); Mark Gallardo, MD; Leon Herndon, MD; Deborah Ristvedt, DO; and Thomas Samuelson, MD. Go here for more information and to register.
Key Glaucoma Presentations:
- Zachary C. Dockter
Implantation of Two Second-Generation Trabecular Micro-Bypass Stents with Cataract Extraction in Open-Angle Glaucoma: Two-Year Outcomes
- Zachary C. Dockter
Trabecular Micro-Bypass Stent Implantation with Cataract Extraction in Primary Open-Angle Glaucoma: Long-Term Results
- Tanner J. Ferguson, MD
Trabecular Micro-Bypass Stent Implantation with Cataract Extraction in Pseudoexfoliative Glaucoma: Seven-Year Results
- Mark J. Gallardo, MD
Implantation of Trabecular Micro-Bypass Stents in Combination with Cataract Surgery in Open-Angle Glaucoma: Reduced IOP & Medication Burden
- Benjamin L. Heller, DO
Real-World Outcomes of Second-Generation Trabecular Micro-Bypass Stent Implantation with Cataract Surgery in Primary Open-Angle Glaucoma
- Jeremy Hu, FRCOphth
Combined iStent inject with Cataract Extraction in Asian Eyes with Primary Open-Angle Glaucoma: One-Year Outcomes
- John Kan, MBBS
12-Month Outcomes of Combined Phacoemulsification and iStent inject in Asian Eyes with Normal-Tension Glaucoma: A Single-Centre Experience
- Karsten Klabe, MD
Minimally-Invasive Glaucoma Surgery: Five-Years - Results with the iStent Inject
- Sophia S. Lam
Outcomes of Second-Generation Trabecular Micro-Bypass Stent (iStent inject) Combined with Phacoemulsification in Open-Angle Glaucoma
- Brian Nguyen, DO
Trabecular Micro-Bypass Stents as First-Line Intervention in Eyes with and without Prior Medication Usage
- Leela Raju, MD
An Evaluation of Three Minimally-Invasive Glaucoma Surgeries (MIGS) Combined with Phacoemulsification for Treatment of Open-Angle Glaucoma
- Ali Salimi, MD, MSc
Comparative Evaluation of Cataract Surgery with and without Trabecular Micro-Bypass Stents in Primary Angle-Closure Glaucoma: One-Year Results
- Ali Salimi, MD, MSc
Three-Year Outcomes of Second-Generation Trabecular Micro-Bypass Stents (iStent inject) with Phacoemulsification in Various Glaucoma Subtypes
- Steven R. Sarkisian Jr., MD
Reduction in IOP and Medication Burden Following Second-Generation Trabecular Micro-Bypass Stent Implantation with Concurrent Cataract Surgery
- Harrison J. Shawa
Longitudinal U.S. Experience with First- and Second-Generation Trabecular Meshwork Micro-Bypass Stents in Combination with Cataract Surgery
- Mitchell C. Shultz, MD, ABO
U.S. Experience with Second-Generation Trabecular Micro-Bypass Implantation with Cataract Surgery, Either with or without Ab-Interno Canaloplasty
Key Corneal Health Presentations:
- Steven A. Greenstein, MD
Ten-Year Follow-Up for Corneal Collagen Cross-Linking in Patients with Keratoconus and Post-Refractive Ectasia
- Abby Nieuwsma, MD
Corneal Cross-Linking Outcomes in Patients with Thin Corneas: Can We Help More Patients with Keratectasia?
- Solin Saleh, MD
Outcomes of Corneal Cross-Linking for Keratoconus in a Pediatric Population
Abstracts and full session details can be found at www.ascrs.org.
Glaukos will also be exhibiting on the showroom floor throughout ASCRS at booth #3025.
The ASCRS Annual Meeting is among the largest gatherings of anterior segment physicians, medical personnel and industry executives in the ophthalmic industry. All educational content of the ASCRS Annual Meeting is planned by its program committee, and ASCRS does not endorse, promote, approve or recommend the use of any products, devices or services.
About Photrexa® Viscous and Photrexa
Indications: Photrexa Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa (riboflavin 5’-phosphate ophthalmic solution) are indicated for use with the KXL® System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.
Important Safety Information: Corneal collagen cross-linking should not be performed on pregnant women. Ulcerative keratitis can occur. Patients should be monitored for resolution of epithelial defects. The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain, light sensitivity, reduced visual acuity and blurred vision. These are not all of the side effects of the corneal collagen cross-linking treatment.
For more information, go to www.livingwithkeratoconus.com/ to obtain the FDA-approved product labeling.
Photrexa Viscous and Photrexa are manufactured for Avedro. The KXL System is manufactured by Avedro. Avedro is a wholly owned subsidiary of Glaukos Corporation.
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012, its next-generation iStent inject device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties include, without limitation, the timing and extent to which obtain regulatory approval for investigational products, our ability to successfully commercialize such products, the ability to obtain and maintain adequate financial coverage and reimbursement for our products, and the continued efficacy and safety profile of our products as might be suggested in the presentations at the ASCRS meeting. These and other risks, uncertainties and factors related to Glaukos and our business are described in detail under the caption “Risk Factors” and elsewhere in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, which was filed with the Securities and Exchange Commission (SEC) on May 6, 2021, and our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the SEC on March 1, 2021. Our filings with the Securities and Exchange Commission are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.